NEW YORK, Feburary 4, 2026 — DSS, Inc. — Leads & Copy —
DSS, Inc. (NYSE: DSS), a multinational company with interests in product packaging, biotechnology, commercial lending, and securities and investment management, has announced the pricing of a firm commitment underwritten public offering. The offering is expected to generate gross proceeds of approximately $1.0 million for the company before deducting underwriting fees and other offering expenses.
The offering consists of 900,000 shares of common stock priced at $1.00 per share. DSS has granted the underwriter an overallotment option to purchase up to an additional 135,000 shares of common stock, representing 15% of the shares offered. This option can be exercised in whole or in part up to 45 days after the date of the prospectus.
The company anticipates aggregate gross proceeds of approximately $900,000, or $1.035 million if the over-allotment option is fully exercised. The transaction is expected to close around February 5, 2026, pending customary closing conditions.
DSS intends to use the net proceeds from the offering, along with existing cash reserves, for general corporate purposes and working capital.
Aegis Capital Corp. is the sole book-running manager for the offering. Sichenzia Ross Ference Carmel LLP is serving as counsel to DSS, while Kaufman & Canoles, P.C. is acting as counsel to Aegis Capital Corp.
The offering is being made under an effective shelf registration statement on Form S-3 (No. 333-281974), previously filed with the SEC on October 31, 2024, and declared effective on November 5, 2024. A final prospectus supplement and accompanying prospectus detailing the terms of the offering will be filed with the SEC and available on the SEC’s website.
Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010. Interested parties should read the prospectus supplement and accompanying prospectus and other documents filed with the SEC for more information about DSS and the offering.
DSS, Inc. operates across several business lines, including product packaging, biotechnology, commercial lending, and securities and investment management. The company’s business model focuses on developing high-growth subsidiaries and unlocking value through strategic IPOs and public listings.
Source: DSS, Inc.
